In8bio, Inc. (INAB) — 8-K Filings

8-K Filings (22)

• IN8BIO, INC. Files 8-K: Material Agreement, Equity Sales — Dec 19, 2025 Risk: medium
  On December 18, 2025, IN8bio, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed
• 8-K Filing — Nov 24, 2025
• IN8bio, Inc. Files 8-K Report — Oct 27, 2025 Risk: low
  On October 27, 2025, IN8bio, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 350 5th Avenue, Suite 5330,
• IN8BIO, INC. Files 8-K Report — Jun 30, 2025 Risk: low
  On June 24, 2025, IN8bio, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. The company's principal executive off
• IN8bio Files 8-K on Security Holder Rights & Financials — Jun 4, 2025 Risk: medium
  IN8bio, Inc. filed an 8-K on June 3, 2025, reporting material modifications to the rights of security holders and financial statements. The company, formerly kn
• IN8BIO, INC. Files 8-K Report — Jun 2, 2025 Risk: low
  On June 2, 2025, IN8BIO, INC. filed an 8-K report. The filing indicates the company's principal executive offices are located at 350 5th Avenue, Suite 5330, New
• IN8bio, Inc. Files 8-K on Shareholder Vote Matters — May 9, 2025 Risk: low
  IN8bio, Inc. filed an 8-K on May 9, 2025, reporting on matters submitted to a vote of security holders as of May 8, 2025. The filing details the company's corpo
• IN8BIO, INC. Files 8-K: Material Agreements & Equity Sales — Apr 28, 2025 Risk: medium
  On April 27, 2025, IN8bio, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and material
• IN8BIO, INC. Files 8-K on Financials — Mar 13, 2025 Risk: low
  On March 13, 2025, IN8bio, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, including the pr
• IN8bio, Inc. Reports Board and Officer Changes — Mar 5, 2025 Risk: medium
  On March 4, 2025, IN8bio, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing indicates the election of new
• IN8bio, Inc. Files 8-K with Financials — Mar 3, 2025 Risk: low
  On March 3, 2025, IN8bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures ra
• IN8BIO, INC. Files 8-K Report — Feb 11, 2025 Risk: low
  On February 11, 2025, IN8bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate activity r
• IN8bio Faces Delisting Concerns, Shareholder Nominations Filed — Feb 7, 2025 Risk: high
  IN8bio, Inc. filed an 8-K on February 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company also reported shareho
• IN8BIO, INC. Files 8-K Report — Dec 10, 2024 Risk: low
  On December 10, 2024, IN8BIO, INC. filed an 8-K report. The filing indicates the company's principal executive offices are located at 350 5th Avenue, Suite 5330
• IN8bio Appoints New Chief Medical Officer — Nov 25, 2024 Risk: medium
  On November 25, 2024, IN8bio, Inc. filed an 8-K report detailing the appointment of Dr. Lawrence M. Cohen as Chief Medical Officer. Dr. Cohen brings extensive e
• IN8bio, Inc. Files 8-K: Loan Agreement & Equity Updates — Oct 1, 2024 Risk: medium
  On September 30, 2024, IN8bio, Inc. entered into a Material Definitive Agreement, specifically a loan agreement with an affiliate of the Company. The company al
• IN8BIO Appoints New CMO, Elects Director — Sep 11, 2024 Risk: medium
  IN8BIO, INC. announced on September 6, 2024, the appointment of Dr. Lawrence M. Cohen as Chief Medical Officer and the election of Ms. Jennifer L. D. Allison to
• IN8BIO, Inc. Files 8-K on Executive Compensation — Sep 6, 2024 Risk: medium
  On August 30, 2024, IN8bio, Inc. filed an 8-K report detailing changes in its executive compensation arrangements. The filing also includes financial statements
• IN8bio, Inc. Files 8-K on Exit Costs and Other Events — Sep 4, 2024 Risk: medium
  IN8bio, Inc. filed an 8-K on August 30, 2024, reporting costs associated with exit or disposal activities and other events. The company, formerly known as Incys
• IN8bio Terminates LLS Collaboration — Aug 12, 2024 Risk: medium
  On August 12, 2024, IN8bio, Inc. filed an 8-K report to disclose the termination of its agreement with The Leukemia & Lymphoma Society (LLS) regarding the devel
• IN8BIO, INC. Files 8-K: Shareholder Vote & Financials — Jun 13, 2024 Risk: low
  On June 12, 2024, IN8bio, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders. The filing also includes other events and
• IN8bio, Inc. Files 8-K Report — Jun 3, 2024 Risk: low
  On June 3, 2024, IN8bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company, formerly k

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX